A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)

Sponsor

U.S. Army Medical Research and Development Command (U.S. Fed)

Overall Status

Withdrawn

CT.gov ID

NCT04203186

Collaborator

Naval Medical Research Center (U.S. Fed)

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

A comparison of Malaria events (symptoms and signs of malaria) experienced by subjects infected with PfSPZ Challenge (NF54) vs. PfSPZ Challenge (7G8).

Condition or Disease	Intervention/Treatment	Phase
Plasmodium Falciparum	Drug: atovaquone-proguanil	N/A

Detailed Description

The single center study is designed as a double-blind, randomized, placebo-controlled CHMI trial with 2 parallel test groups to directly compare clinical and laboratory characteristics of the NF54 and 7G8 strains of PfSPZ Challenge. This study will also evaluate signatures of and time to parasitemia by multiple methods and evaluate physiologic status data collected by non-invasive wearable monitors before and during Plasmodium falciparum infection to characterize and trend physiologic changes appearing prior to the onset of parasitemia.

PfSPZ Challenge (aseptic, purified, cryopreserved, infectious Plasmodium falciparum sporozoites) or normal saline will be administered by direct venous inoculation (DVI) by 25-gauge needle and syringe to healthy malaria naïve adults.

Data generated from samples collected for biomarker assay analysis will be useful for developing predictive models to evaluate the efficacy of malaria vaccine candidates.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

2 parallel test groups to directly compare clinical and laboratory characteristics2 parallel test groups to directly compare clinical and laboratory characteristics

Masking:

Triple (Participant, Care Provider, Investigator)

Masking Description:

double-blind, randomized, placebo-controlled trial

Primary Purpose:

Diagnostic

Official Title:

A Phase 1 Clinical Trial To Evaluate The Safety and Infectivity Of Direct Venus Inoculation of Aseptic, Purified, Cryopreserved Plasmodium Falciparum 7G8 And NF54 Challenge Strains (PfSPZ) in a Head-To-Head Comparative Study

Anticipated Study Start Date :

Mar 1, 2020

Anticipated Primary Completion Date :

Jun 1, 2021

Anticipated Study Completion Date :

Sep 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Group 1 - PfSPZ, (NF54) strain Group 1 (N=9) will receive PfSPZ Challenge (NF54) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum (Pf) NF54 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe	Drug: atovaquone-proguanil Malaria standard treatment regimen Other Names: artemether/lumefantrine (AL; Coartem)
Active Comparator: Group 2 - PfSPZ, (7G8) strain Group 2 (N=9) will receive PfSPZ Challenge (7G8) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum 7G8 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe	Drug: atovaquone-proguanil Malaria standard treatment regimen Other Names: artemether/lumefantrine (AL; Coartem)

Arm

Intervention/Treatment

Active Comparator: Group 1 - PfSPZ, (NF54) strain

Group 1 (N=9) will receive PfSPZ Challenge (NF54) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum (Pf) NF54 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe

Drug: atovaquone-proguanil

Malaria standard treatment regimen

Other Names:

artemether/lumefantrine (AL; Coartem)

Active Comparator: Group 2 - PfSPZ, (7G8) strain

Group 2 (N=9) will receive PfSPZ Challenge (7G8) A one-time dose of 3,200 aseptic, purified, cryopreserved, non-attenuated Plasmodium falciparum 7G8 sporozoites (Pf SPZ Challenge) Mode of administration: Direct venous inoculation (DVI) through a 25 gauge needle and syringe

Drug: atovaquone-proguanil

Malaria standard treatment regimen

Other Names:

artemether/lumefantrine (AL; Coartem)

Outcome Measures

Primary Outcome Measures

Difference in the pre-patent period [29 days]
The difference in the time of first malaria event (symptom or sign of malaria),in subjects infected with PfSPZ Challenge (NF54) vs. PfSPZ Challenge (7G8)
Difference in the total number of malaria events [29 days]
The difference in the total number of Grade 2 or greater malaria events (symptoms and signs of malaria) experienced by subjects infected with PfSPZ Challenge (NF54) vs PfSPZ Challenge (7G8)

Secondary Outcome Measures

Determine differences in pre-patent periods [29 days]
Determine differences in prepatent periods in subjects infected with PfSPZ Challenge (NF54) vs PfSPZ Challenge (7G8) as detected by TBS, RDT, hsRDT and by PCR
Determine differences in the growth rate of parasites [29 days]
Determine differences in the growth rate of parasites in the blood of subjects infected by PfSPZ Challenge (NF54) vs PfSPZ Challenge (7G8) as detected by PCR

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 45 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Adults (male or non-lactating, non-pregnant female)
Between the ages of 18 and 45 (inclusive) at the time of enrollment
Body weight equal to or greater than 110 lbs
Available and willing to participate for duration of study
Able and willing to provide a written informed consent
Able to complete an Assessment of Understanding with a score of at least 80% correct
In good general health with no clinically significant health problems as established by medical history, physical examination, and laboratory screening
Sexually active females, unless surgically sterile or at least 1 year post-menopausal, must use an effective method of avoiding pregnancy (Section 5.4.5.3) from 14 days prior to CHMI and agree to continue using such precautions during the study until at least 2 months after CHMI
If female subjects are unable to bear children due to menopause or have had a procedure performed (e.g. tubal ligation or hysterectomy), a medical note from a physician is required
If post-menopausal, subjects must have experienced at least 1 year of amenorrhea and provide a medical note from her physician documenting this medical history
Agree not to travel to a malaria endemic area during the course of the study
Agree to refrain from blood donation from the time of CHMI and for 3 years following CHMI
Must be willing to take anti-malarial treatment after CHMI
Must agree to stay in a pre-determined hotel near the NMRC CTC from approximately 7 days after CHMI until antimalarial treatment is completed or through 18 days post CHMI
For active-duty military personnel, documentation of their command's approval to participate

Exclusion Criteria:

Pregnant (positive urine pregnancy test) or nursing at screening or plans to become pregnant or nurse at any period from the time of enrollment through 56 days after CHMI.
Receipt of any investigational malaria vaccine
Any history of malaria infection
Travel to a malaria endemic region within 6 months of enrollment or during the study (from enrollment through 2 months after CHMI)
History of long-term residence (>5 years) in an area known to have significant transmission of P falciparum (http://www.cdc.gov/malaria/map/)
History of clinically significant contact dermatitis
Seropositive for the human immunodeficiency virus (HIV), hepatitis C virus (HCV), and/or hepatitis B surface antigen (HBsAg)
Positive sickle cell screening test, including evidence of sickle cell trait or sickle cell anemia (due to its effect on subject's susceptibility to malaria)
History of thalassemia or thalassemia trait (due to its effect on subject's susceptibility to malaria)
Participation in any clinical study involving another investigational vaccine, drug, or other products within 60 days prior to enrollment or plan to participate in such a clinical study during or within 1 month following the active study phase of the study (from the day enrollment through 2 months after CHMI)
Allergy to any component of the PfSPZ Challenge formulation, Malarone® (atovaquone-proguanil), and/or Coartem® (artemether-lumefantrine)
History of porphyria